MX2024000829A - Proteinas actrii y usos de las mismas. - Google Patents

Proteinas actrii y usos de las mismas.

Info

Publication number
MX2024000829A
MX2024000829A MX2024000829A MX2024000829A MX2024000829A MX 2024000829 A MX2024000829 A MX 2024000829A MX 2024000829 A MX2024000829 A MX 2024000829A MX 2024000829 A MX2024000829 A MX 2024000829A MX 2024000829 A MX2024000829 A MX 2024000829A
Authority
MX
Mexico
Prior art keywords
telangiectasia
risk
effective amount
therapeutically effective
patient receiving
Prior art date
Application number
MX2024000829A
Other languages
English (en)
Inventor
Oliveira Pena Janethe De
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2024000829A publication Critical patent/MX2024000829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En algunos aspectos, la divulgación se refiere a composiciones y métodos para disminuir el riesgo de telangiectasia en un paciente que recibe una cantidad terapéuticamente efectiva de un polipéptido de ActRII, particularmente un régimen de dosificación que disminuye el riesgo de telangiectasia en un paciente que recibe una cantidad terapéuticamente efectiva de un polipéptido de ActRII.
MX2024000829A 2021-07-19 2022-07-18 Proteinas actrii y usos de las mismas. MX2024000829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19
PCT/US2022/037479 WO2023003815A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2024000829A true MX2024000829A (es) 2024-04-12

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000829A MX2024000829A (es) 2021-07-19 2022-07-18 Proteinas actrii y usos de las mismas.

Country Status (16)

Country Link
US (1) US20240327494A1 (es)
EP (1) EP4373577A1 (es)
JP (1) JP2024526820A (es)
KR (1) KR20240049857A (es)
CN (1) CN117957014A (es)
AU (1) AU2022316103A1 (es)
CA (1) CA3225613A1 (es)
CL (1) CL2024000151A1 (es)
CO (1) CO2024001551A2 (es)
CR (1) CR20240061A (es)
DO (1) DOP2024000016A (es)
EC (1) ECSP24012819A (es)
IL (1) IL310141A (es)
MX (1) MX2024000829A (es)
PE (1) PE20240777A1 (es)
WO (1) WO2023003815A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
AU2016359695A1 (en) * 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
PT3496739T (pt) * 2016-07-15 2021-06-21 Acceleron Pharma Inc Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar

Also Published As

Publication number Publication date
ECSP24012819A (es) 2024-03-01
CN117957014A (zh) 2024-04-30
AU2022316103A1 (en) 2024-02-08
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
US20240327494A1 (en) 2024-10-03
CO2024001551A2 (es) 2024-03-07
IL310141A (en) 2024-03-01
JP2024526820A (ja) 2024-07-19
DOP2024000016A (es) 2024-06-16
CA3225613A1 (en) 2023-01-26
EP4373577A1 (en) 2024-05-29
CR20240061A (es) 2024-05-02
WO2023003815A1 (en) 2023-01-26
CL2024000151A1 (es) 2024-08-09
WO2023003815A9 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
CY1123657T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2022003414A (es) Celulas efectoras con multiples objetivos y uso de las mismas.
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
ZA202200648B (en) Immunoglobulins and uses thereof
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12019502444A1 (en) Formulations of human anti-rankl antibodies, and methods of using the same
MX2022014422A (es) Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MY193519A (en) Method for decreasing immunogenicity of protein and peptide
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
ZA202304485B (en) Bispecific antibody against alpha-syn/igf1r and use thereof
NZ762312A (en) Anti-pacap antibody
MX2021007047A (es) Formulaciones de anticuerpos.
MX2023001160A (es) Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.
MX2024000829A (es) Proteinas actrii y usos de las mismas.
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2022014455A (es) Formulacion de anticuerpo anti-clever-1 estable.
MA51717B1 (fr) Anticorps anti-cd63, conjugués et leurs utilisations